Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines

John A. Thompson, Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew Frigault, Benjamin H. Kaffenberger, Matthew Lunning, Suzanne McGettigan, Jordan McPherson, Nisha A. Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan OluwoleSandip P. Patel, Nathan Pennell, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Ryan M. Weight, Alyse Johnson-Chilla, Griselda Zuccarino-Catania, Anita Engh

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Abstract

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.

Original languageEnglish (US)
Pages (from-to)231-241
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume18
Issue number3
DOIs
StatePublished - 2020

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this